Start-Up Previews (06/2010)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. "Altering The Insulin Resistance System" features profiles of Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia BIotech and Rhythm Pharmaceuticals. Plus these Start-Ups Across Health Care: nContact Surgical, NormOxys and Thermopeutix.
You may also be interested in...
ThermopeutiX Inc.
Patients afflicted with acute stroke may soon have their brain protected from reduced cerebral blood flow by being induced with selective hypothermia, as opposed to being subjected to systemic cooling, which lowers the entire body's temperature, but may stop the heart in the process. ThermopeutiX Inc.'s DuoFlo is a dual-lumen catheter system that removes warm blood from the body through one lumen and delivers cold blood to the brain through a second lumen. The novel technology is designed to be used primarily by interventional cardiologists and interventional radiologists -- rather than neurologists -- to treat not only stroke, but cardiac arrest and trauma as well.
nContact Surgical Inc.
nContact Surgical Inc. aims to merge the best of surgical and interventional techniques to provide a truly minimally invasive, single procedure solution for atrial fibrillation patients. Its Numeris Coagulation system with VisiTrax is used in the surgical portion of the procedure, in which VisiTrax integrates suction, perfusion and radiofrequency energy to create long linear lesions on the outside of a beating heart. The electrophysiologist then uses a catheter to complete the biatrial lesion pattern inside the heart.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.